Pharmaceutical - USA, Ophthalmics

Filter

Current filters:

USAOphthalmics

Popular Filters

Nicox holds successful pre-NDA meeting with FDA for AC-170

Nicox holds successful pre-NDA meeting with FDA for AC-170

26-01-2015

French ophthalmics company Nicox has held a positive pre-New Drug Application meeting with the US Food…

AC-170NicOxOphthalmicsPharmaceuticalRegulationUSA

Novartis' Alcon granted additional pediatric indication by the European Commission for Travatan

Novartis' Alcon granted additional pediatric indication by the European Commission for Travatan

23-12-2014

Eyecare specialist Alcon, the second-largest division of Swiss drug major Novartis, has been granted…

AlconNovartisOphthalmicsPharmaceuticalRegulationTravatanUSA

Age-related macular degeneration treatment market to reach $10 billion by 2023

Age-related macular degeneration treatment market to reach $10 billion by 2023

04-12-2014

The market for treatments of age-related macular degeneration across seven major countries will almost…

AvastinEuropeEyleaFovistaLucentisMarkets & MarketingOphthalmicsPharmaceuticalUSA

Apellis Pharma to acquire former parent Potentia

Apellis Pharma to acquire former parent Potentia

26-11-2014

USA-based Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals,…

Apellis PharmaceuticalsMergers & AcquisitionsOphthalmicsPharmaceuticalPotentia PharmaceuticalsUSA

US FDA approves Iluvien for diabetic macular edema

US FDA approves Iluvien for diabetic macular edema

28-09-2014

US ophthalmic drug specialist Alimera Sciences says that the US Food and Drug Administration has approved…

Alimera SciencesIluvienMedidurOphthalmicsPharmaceuticalpSividaRegulationTethadurUSA

Report shows Eylea and Lucentis are equally likely to be covered by payers

Report shows Eylea and Lucentis are equally likely to be covered by payers

19-09-2014

Recently launched anti-vascular endothelial growth factor (VEGF) agent Eylea (aflibercept), from USA-based…

EyleaFinancialGenentechLucentisOphthalmicsPharmaceuticalRegeneron PharmaceuticalsUSA

Nicox and Bausch + Lomb to co-promote latanoprostene bunod for glaucoma

Nicox and Bausch + Lomb to co-promote latanoprostene bunod for glaucoma

08-08-2014

International opthalmic company Nicox is to co-promote latanoprostene bunod with Bausch + Lomb, the eyecare…

Bausch & LombCanadaGlaucomaLatanoprost OphthalmicMarkets & MarketingNicOxOphthalmicsOpticsPharmaceuticalUSA

US FDA delays Allergan’s Semprana decision, approves Ozurdex

US FDA delays Allergan’s Semprana decision, approves Ozurdex

01-07-2014

US drugmaker Allergan, the subject of a hostile $53 billion takeover pursuit by Canada’s Valeant Pharmaceuticals…

AllerganBimatoprost Ophthalmic Solution 0.03% for GlaLevadexNeurologicalOphthalmicsOzurdexPharmaceuticalRegulationResearchSempranaUSA

US retinal specialists very receptive to pipeline agents for dry-AMD

US retinal specialists very receptive to pipeline agents for dry-AMD

05-06-2014

Surveyed US retinal specialists are highly willing to prescribe key emerging therapies for the treatment…

emixustatGlaxoSmithKlineGSK-933776Markets & MarketingOphthalmicsOtsukaPharmaceuticalResearchUSA

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

AbbVie gains FDA orphan designation for Humira in uveitis

21-05-2014

The US Food and Drug Administration granted US drugmaker AbbVie’s blockbuster rheumatoid arthritis…

AbbVieHumiraOphthalmicsPharmaceuticalRegulationUSA

Alimera resubmits NDA for Iluvien

Alimera resubmits NDA for Iluvien

27-03-2014

US ophthalmic pharma specialist Alimera Sciences has resubmitted its New Drug Application for Iluvien…

AlimeraAlimera SciencesIluvienOphthalmicsPharmaceuticalRegulationUSA

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Allergan faces law suit alleging payment of kickbacks to optometrists to prescribe Restasis

Allergan faces law suit alleging payment of kickbacks to optometrists to prescribe Restasis

14-02-2014

US drugmaker Allergan (NYSE: AGN) is the subject of legal action after allegations that it paid kickbacks…

AllerganLegalOphthalmicsPharmaceuticalRestasisUSA

Bayer files VEGF Trap-Eye for myopic choroidal neovascularization in Japan

Bayer files VEGF Trap-Eye for myopic choroidal neovascularization in Japan

29-11-2013

German drug major Bayer (BAYN: DE) has submitted VEGF Trap-Eye, already marketed under the brand name…

Asia-PacificBayerEyleaOphthalmicsPharmaceuticalRegeneronRegulationUSA

Back to top